JP2008543869A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543869A5
JP2008543869A5 JP2008517147A JP2008517147A JP2008543869A5 JP 2008543869 A5 JP2008543869 A5 JP 2008543869A5 JP 2008517147 A JP2008517147 A JP 2008517147A JP 2008517147 A JP2008517147 A JP 2008517147A JP 2008543869 A5 JP2008543869 A5 JP 2008543869A5
Authority
JP
Japan
Prior art keywords
epitope
product
nucleic acid
seq
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008517147A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543869A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/023499 external-priority patent/WO2006138568A2/en
Publication of JP2008543869A publication Critical patent/JP2008543869A/ja
Publication of JP2008543869A5 publication Critical patent/JP2008543869A5/ja
Pending legal-status Critical Current

Links

JP2008517147A 2005-06-17 2006-06-16 癌腫のための多価同調・増幅免疫療法 Pending JP2008543869A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69158105P 2005-06-17 2005-06-17
PCT/US2006/023499 WO2006138568A2 (en) 2005-06-17 2006-06-16 Multivalent entrain-and-amplify immunotherapeutics for carcinoma

Publications (2)

Publication Number Publication Date
JP2008543869A JP2008543869A (ja) 2008-12-04
JP2008543869A5 true JP2008543869A5 (cg-RX-API-DMAC10.html) 2009-08-06

Family

ID=37309646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008517147A Pending JP2008543869A (ja) 2005-06-17 2006-06-16 癌腫のための多価同調・増幅免疫療法

Country Status (13)

Country Link
US (2) US8084592B2 (cg-RX-API-DMAC10.html)
EP (2) EP2465530A1 (cg-RX-API-DMAC10.html)
JP (1) JP2008543869A (cg-RX-API-DMAC10.html)
KR (1) KR20080033271A (cg-RX-API-DMAC10.html)
CN (1) CN101687020A (cg-RX-API-DMAC10.html)
AU (1) AU2006259221B8 (cg-RX-API-DMAC10.html)
BR (1) BRPI0611795A2 (cg-RX-API-DMAC10.html)
CA (1) CA2612518A1 (cg-RX-API-DMAC10.html)
IL (1) IL188107A (cg-RX-API-DMAC10.html)
MX (1) MX2007015950A (cg-RX-API-DMAC10.html)
NZ (2) NZ587601A (cg-RX-API-DMAC10.html)
SG (1) SG162818A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006138568A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP1838342A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
AU2008306190A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of bubuc and optionally EAA-MART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
KR20100061481A (ko) * 2007-09-11 2010-06-07 몬도바이오테크 래보래토리즈 아게 치료제로서의 미니가스트린
CN102973950B (zh) * 2011-09-06 2015-05-27 四川百利药业有限责任公司 Prame、wt1双价肿瘤dna疫苗
EP2908851A1 (en) * 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
US10462442B2 (en) * 2012-12-20 2019-10-29 Brett I. Walker Apparatus, systems and methods for monitoring vehicular activity
KR101992040B1 (ko) * 2015-06-24 2019-06-21 코어포토닉스 리미티드 접이식 렌즈 카메라용 저-프로파일 3-축 액추에이터
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的hla展示肽
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20230190807A1 (en) * 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Tcr compounds, compositions, and methods of treating

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
US5804381A (en) * 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
CA2051375C (en) * 1989-05-04 2000-09-12 Dennis J. Henner Process and compositions for the isolation of human relaxin
US5320886A (en) * 1991-11-14 1994-06-14 American Dental Association Health Foundation Hydrophilic crosslinking monomers and polymers made therefrom
EP1757695A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5747271A (en) 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) * 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
ES2265165T3 (es) 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US7334705B2 (en) 2001-02-26 2008-02-26 Kao Corporation Container
WO2002069907A2 (en) 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
JP3830382B2 (ja) 2001-03-14 2006-10-04 日本碍子株式会社 セラミック焼結体およびその製造方法
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
WO2004005891A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
US20040019571A1 (en) 2002-07-26 2004-01-29 Intel Corporation Mobile communication device with electronic token repository and method
AU2003261254A1 (en) * 2002-07-31 2004-02-16 Ludwig Institute For Cancer Research Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
JP5127224B2 (ja) 2003-06-17 2013-01-23 マンカインド コーポレイション 予防又は治療目的のためのmhcクラスi拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
US20050118186A1 (en) 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
WO2005007839A1 (ja) * 2003-07-22 2005-01-27 Kirin Beer Kabushiki Kaisha ノッチリガンドDelta-1、GM-CSF、TGF-βを用いたヒト末梢血単核球であるCD14陽性細胞からのランゲルハンス細胞の調製方法
ATE496129T1 (de) * 2003-07-22 2011-02-15 Ludwig Inst Cancer Res Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
WO2006071989A2 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
CA2592922A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP2385059A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7511118B2 (en) * 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
US9814289B2 (en) 2015-04-08 2017-11-14 Otter Products, Llc Protective folio case for an electronic device
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Similar Documents

Publication Publication Date Title
PH12019502194A1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP2017171685A5 (cg-RX-API-DMAC10.html)
EA201791519A1 (ru) Новая иммунотерапия против нейрональных опухолей и опухолей головного мозга
JP2017006120A5 (cg-RX-API-DMAC10.html)
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
EP3545965A3 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
EA201100586A1 (ru) Новая иммунотерапия против нескольких видов опухолей, включая нейрональные опухоли и опухоли головного мозга
EA201590986A1 (ru) Антитела к ceacam5 и их применения
WO2015169945A3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
WO2004016643A3 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
WO2006138745A3 (en) Therapeutic peptides and vaccines
EP2545171A4 (en) HJURP PEPTIDES AND VACCINES CONTAINING THEM
ATE524494T1 (de) Plasmid-kodierung für p185- proteinsequenzvarianten und therapeutische anwendungen davon
MY198397A (en) Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer
CN103965165A (zh) 一种抑制凋亡抑制蛋白的异喹啉化合物及其制备方法与应用
TH176462A (th) การรักษาทางภูมิคุ้มกันใหม่ต่อหลายเนื้องอกรวมทั้งมะเร็งกระเพาะอาหารและลำไส้และกระเพาะอาหาร
NZ770913A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers